NCT07070076 A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
| NCT ID | NCT07070076 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Li Qiang |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 286 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2030-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 286 participants in total. It began in 2026-08-01 with a primary completion date of 2030-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this clinical trial is to compare the effects of yttrium-90 (SIRT) treatment and hepatic arterial perfusion chemotherapy (HAIC) on progression-free survival (PFS) in patients with potentially resectable HCC in the HCC population. The main questions it aims to answer are: * Whether yttrium-90 (SIRT) therapy is more effective than hepatic arterial infusion chemotherapy (HAIC) in treating patients with potentially resectable liver cancer * Whether yttrium-90 (SIRT) therapy is safer than hepatic arterial perfusion chemotherapy (HAIC) in patients with potentially resectable liver cancer The researchers compared yttrium-90 (SIRT) treatment to hepatic arterial perfusion chemotherapy (HAIC) to see if yttrium-90 (SIRT) was more effective in treating potentially resectable liver cancer. Participants will: * Patients will receive yttrium-90 (SIRT) therapy or 1 of them hepatic arterial perfusion chemotherapy (HAIC). * Follow-up at 1, 3, and 6 months after surgery * Keep a record of their symptoms and test results
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years and ≤ 75 years. * Good general condition, with an ECOG Performance Status (PS) of 0-1. * Classified as China Liver Cancer Staging (CNLC) stage Ib (PS 0-2, Child-Pugh class A/B liver function, single tumor \>5 cm in diameter, without radiologically visible vascular tumor thrombus and extrahepatic metastasis), IIa (PS 0-2, Child-Pugh class A/B liver function, 2-3 tumors with the largest diameter \>3 cm, without radiologically visible vascular tumor thrombus and extrahepatic metastasis), IIb (PS 0-2, Child-Pugh class A/B liver function, ≥4 tumors regardless of diameter, without radiologically visible vascular tumor thrombus and extrahepatic metastasis), or IIIa (PS 0-2, Child-Pugh class A/B liver function, any tumor status with radiologically visible vascular tumor thrombus but without extrahepatic metastasis). * No prior treatment for liver cancer. * Absence of distant metastasis, with the tumor anticipated to be completely resectable. * Patient provides written informed consent after being fully informed about the study. Exclusion Criteria: * Presence of severe impairment of heart, brain, lung, kidney, or other major organ function, severe concurrent infection, or other serious comorbid conditions (\> Grade 2 adverse events per CTCAE Version 4.03), rendering the patient unable to tolerate the treatment. * History of other malignancies. * History of allergy to related drugs. * History of organ transplantation. * Prior treatment for the tumor (including interferon). * Concurrent HIV infection. * History of drug or substance abuse. * Occurrence of gastrointestinal bleeding or cardiovascular/cerebrovascular events within approximately 30 days prior to treatment. * Pregnant or lactating women, or women of childbearing potential unwilling to use contraception. * Concurrent psychiatric disorders that prevent the patient from providing informed consent or interfere with receiving treatment. * Any other factors deemed by the investigator as likely to affect patient enrollment or the evaluation of results.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07070076 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07070076 currently recruiting?
Yes, NCT07070076 is actively recruiting participants. Contact the research team at liqiang@jnu.edu.cn for enrollment information.
Where is the NCT07070076 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07070076 clinical trial?
NCT07070076 is sponsored by Li Qiang. The trial plans to enroll 286 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.